Everolimus Plus Octreotide Long-Acting Repeatable in Patients With Colorectal Neuroendocrine Tumors: A Subgroup Analysis of the Phase III RADIANT-2 Study

Castellano, Daniel; Bajetta, Emilio; Panneerselvam, Ashok; Saletan, Stephen; Kocha, Walter; O'Dorisio, Thomas M.; Anthony, Lowell; Hobday, Timothy J.

doi:10.1634/theoncologist.2012-0263

Cited by 58 publications

(55 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Chemotherapy is mainly used to treat patients with NEC or MANEC, while NETs have low sensitivity to chemotherapy (29,30). Biotherapy and molecular targeted therapy have good prospects in the treatment of patients with progressive NET (31). In the present study, all 74 cases of GINEN underwent surgery with different surgical scope; 12 cases underwent postoperative chemotherapy; and 5 cases underwent postoperative biotherapy and molecular targeted therapy.…”

Section: Discussionmentioning

confidence: 81%

Retrospective analysis of the clinicopathological characteristics of gastrointestinal neuroendocrine neoplasms

Wang

Chen

et al. 2015

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. The aim of the present study was to analyze and summarize the clinicopathological characteristics and factors affecting prognosis for patients with gastrointestinal neuroendocrine neoplasms (GINENs). Retrospective analysis was conducted on the clinicopathological data of 74 patients who were diagnosed with GINEN, and immunohistochemical methods were used to detect the expression levels of relevant markers [synaptophysin (Syn), chromogranin A (CgA) and . Among the 74 cases with GINEN, there were 39 males and 35 females, with an average age of 56.9 years. There were 32 neoplasms in the rectum, 29 in the stomach, 6 in the colon, 2 in the small intestine and 5 in the appendix. All 74 cases underwent surgical resection. According to the World Health Organization Classification of Tumors of the Digestive System (2010), the diagnosis of the 74 cases showed 41 cases (55.4%) of neuroendocrine tumor (NET; 25 cases of G1 and 16 cases of G2), 21 cases (28.4%) of neuroendocrine carcinoma (NEC) and 12 cases (16.2%) of mixed adenoneuroendocrine carcinoma (MANEC). Additionally, 19 cases had metastasis to lymph nodes. During 10-34 months of follow-up, 15 patients had distant metastasis and 24 patients succumbed, and the accumulative survival rate in 1 or 2 years was 87.8 and 74.3%, respectively. Six factors, namely neoplasm size, depth of invasion, lymph node metastasis, distant metastasis, pathological type and the expression or lack of expression of CgA, significantly affected the survival time of patients. Definitive diagnosis of GINEN mainly relies on pathological diagnosis. GINENs with different histopathological types and grading have different clinicopathological characteristics and prognosis: NETs are mainly early lesions with a good prognosis, whereas NECs and MANECs have high malignancy and strong invasion with a worse prognosis.

show abstract

Section: Discussionmentioning

confidence: 81%

Retrospective analysis of the clinicopathological characteristics of gastrointestinal neuroendocrine neoplasms

Wang

Chen

et al. 2015

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

show abstract

“…In the case of disseminated neoplastic process with the symptoms of excessive serotonin secretion, using SSA is the treatment of choice (evidence level 1). In non-functional neuroendocrine neoplasms (NF-NENs), there is no conclusive evidence of anti-neoplastic effectiveness of somatostatin analogues [12], but their effectiveness may not be excluded, due to the recently published results of the CLARINET, RADIANT-2 study and Polish observations [33,59,64].…”

Section: Biotherapy Somatostatin Analogues (Ssa) M-tor Inhibitorsmentioning

confidence: 99%

Nowotwory neuroendokrynne jelita grubego — zasady postępowania (rekomendowane przez Polską Sieć Guzów Neuroendokrynnych)

Starzyńska

Deptała

Królicki

et al. 2014

Endokrynologia Polska

View full text Add to dashboard Cite

Neuroendocrine neoplasms of the large intestine account for 20% of all neuroendocrine neoplasms (NENs) and are most commonly found in the rectum. The rate of detection of colorectal NENs is increasing, and this tendency will continue due to the widespread use of colonoscopy as a screening tool and the removal of all diagnosed lesions. This paper provides updated guidelines for the management of patients with colorectal NENs. Recent data on epidemiology, clinical characteristics, biochemical, and pathomorphological diagnosis as well as useful imaging techniques are presented. We look in detail at novel methods of treatment including endoscopic and surgical management, pharmacological and radioisotope therapy. We summarise monitoring of the treatment. (Endokrynol Pol 2013; 64 (6): 494-504)

show abstract

“…In the case of a disseminated neoplastic process with the symptoms of excessive serotonin secretion, using somatostatin analogues is the treatment of choice (*evidence level 1) [46]. In nonfunctional neuroendocrine neoplasms (NF-NENs), there is no conclusive evidence of the anti-neoplastic effectiveness of SSA, but their effectiveness may not be excluded, due to the results of the CLARINET and RADIANT-2 studies [47,48].…”

Section: Biotherapy Somatostatin Analogues (Ssa)mentioning

confidence: 99%

“…The CLARINET study did not demonstrate any clear advantages of using lanreotide; however, the data regarding neuroendocrine neoplasms of the large intestine in this subgroup was too limited to draw any conclusions. Everolimus is recommended in non-resectable, locally advanced and/or metastatic colorectal NENs (G1 and G2) as a second-line therapy, if SSA treatment is ineffective, or as a third-line therapy, if SAA and/or interferon alpha (INF-α) (currently unavailable in Poland) and PRRT therapy is unsuccessful [46,49].…”

Section: Szkolenie Podyplomowe Targeted Therapy -M-tor Inhibitors (Evmentioning

confidence: 99%

See 1 more Smart Citation

Nowotwory neuroendokrynne jelita grubego — zasady postępowania (rekomendowane przez Polską Sieć Guzów Neuroendokrynnych)

Starzyńska¹,

Londzin-Olesik

Bałdys-Waligórska

et al. 2017

Endokrynologia Polska

View full text Add to dashboard Cite

Everolimus Plus Octreotide Long-Acting Repeatable in Patients With Colorectal Neuroendocrine Tumors: A Subgroup Analysis of the Phase III RADIANT-2 Study

Abstract: ABSTRACT

Cited by 58 publications

References 27 publications

Retrospective analysis of the clinicopathological characteristics of gastrointestinal neuroendocrine neoplasms

Retrospective analysis of the clinicopathological characteristics of gastrointestinal neuroendocrine neoplasms

Nowotwory neuroendokrynne jelita grubego — zasady postępowania (rekomendowane przez Polską Sieć Guzów Neuroendokrynnych)

Nowotwory neuroendokrynne jelita grubego — zasady postępowania (rekomendowane przez Polską Sieć Guzów Neuroendokrynnych)

Contact Info

Product

Resources

About